Shire drops drug’s new use after phase three disappointment
Shire's ADHD drug lisdexamfetamine (Vyvanse) failed to meet endpoints in two phase three trials evaluating a new role in depression.
The "disappointment" has led the company to decide to drop further investigation for the extended indication.
Related news:
Shire ends research into Vyvanese's use in depression (The Wall Street Journal).
Shire's ADHD drug Vyvanse fails in trial to treat depression (Reuters).
Reference links:
Shire reports top-line results from two phase 3 studies for Vyvanse (lisdexamfetamine dimesylate) capsules (CII) as an adjunctive treatment for adults with major depressive disorder (Shire press release).